Laboratory Corporation of America Holdings (LH)
| Market Cap | 17.41B |
| Revenue (ttm) | 12.30B |
| Net Income (ttm) | 433.10M |
| Shares Out | 84.29M |
| EPS (ttm) | 5.06 |
| PE Ratio | 40.95 |
| Forward PE | 13.19 |
| Dividend | $2.88 (1.39%) |
| Ex-Dividend Date | May 28, 2024 |
| Volume | 317,399 |
| Open | 206.34 |
| Previous Close | 206.15 |
| Day's Range | 205.46 - 207.60 |
| 52-Week Range | 179.59 - 234.09 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 242.00 (+17.15%) |
| Earnings Date | Apr 25, 2024 |
About LH
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepa... [Read more]
Financial Performance
In 2023, LH's revenue was $12.16 billion, an increase of 2.51% compared to the previous year's $11.86 billion. Earnings were $418.00 million, a decrease of -67.32%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for LH stock is "Buy." The 12-month stock price forecast is $242.0, which is an increase of 17.15% from the latest price.
News
Labcorp to Webcast Its Annual Meeting of Shareholders
BURLINGTON, N.C. , May 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be ...
Invitae Receives Court Approval for Sale to Labcorp
Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases Key milestone reached in Invitae's Chapter 11 process BURLINGTON, N.C. and SAN FRANCISCO , May...
FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
WASHINGTON — Makers of medical tests that have long escaped government oversight will have about four years to show that their new offerings deliver accurate results, under a government rule vigorousl...
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B
Assay expands company's leadership in precision medicine and cell and gene therapy BURLINGTON, N.C. , April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive...
Labcorp beats quarterly estimates on strong testing demand
Labcorp beat Wall Street expectations for first-quarter profit on Thursday, as growing demand for specialty tests boosted sales at its diagnostics business.
Labcorp Announces 2024 First Quarter Results
Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year: Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% Diluted EPS: $2....
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln
Laboratory service provider Labcorp said on Wednesday it will acquire Softbank-backed Invitae Corp's assets auctioned through a voluntary bankruptcy protection process, a few months after the genetic ...
Labcorp Announces Winning Bid for Select Assets of Invitae
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N...
Invitae Enters into Agreement with Labcorp for Sale of Business
– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's As...
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C. , April 15, 2...
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C. , April 11, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a ca...
Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit
The first at-home mpox testing kit provides patients with convenience and privacy to test for mpox, supports physicians in detection and treatment BURLINGTON, N.C. , April 10, 2024 /PRNewswire/ -- Lab...
Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs
Portfolio expansion solidifies company's commitment to advancing cancer research and patient care BURLINGTON, N.C. , April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and...
Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research
Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer BURLINGTON, N.C. , April 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global...
Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research
Researchers to present on topics ranging from molecular residual disease and immunotherapy to whole-genome sequencing BURLINGTON, N.C. , April 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global lead...
Xcell Biosciences Strengthens Cell and Gene Therapy Collaboration With Labcorp
SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has added new elements to its research c...
The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab
Expanded partnership to help increase patient access to critical genetic screening services including genetic counseling and test result turnaround time HOUSTON , March 29, 2024 /PRNewswire/ -- The P...
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- L...
Labcorp to Announce First Quarter Financial Results on April 25, 2024
BURLINGTON, N.C. , March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2...
Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials
Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care BURLINGTON, N.C. , March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: L...
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer
Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C. , March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and com...
Labcorp Launches Weight Loss Management Testing Solutions
New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C. , March 7, 2024 /PRNewswire/...
Labcorp forecasts 2024 profit above estimates on strong testing demand
Laboratory Corporation of America on Thursday forecast 2024 profit above Wall Street expectations and beat fourth-quarter profit estimates, as resilient demand for routine test kits boosted sales in i...
Labcorp Announces 2023 Fourth Quarter and Full Year Results
Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year: Revenue: Q4 of $3.03 billion vs $2.93 billion; Full year of $12.16 billion vs $...